TherapeuticsMD, Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
TherapeuticsMD, Inc. (TXMD) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $264.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2025-03-27
- TherapeuticsMD, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2024-06-30 was $96.00K, a 78.03% decline year-over-year.
- TherapeuticsMD, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2024-03-31 was $111.00K, a 77.02% decline year-over-year.
- TherapeuticsMD, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2023-06-30 was $437.00K.
- TherapeuticsMD, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2023-03-31 was $483.00K.
- TherapeuticsMD, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $264.00K, a 79.23% decline from fiscal 2023.
- TherapeuticsMD, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $1.27M.
- TherapeuticsMD, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2012 was $1.83M, a 899.19% increase from fiscal 2011.
- TherapeuticsMD, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2011 was $183.35K, a 3.24% increase from fiscal 2010.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|
| 2024-12-31 | $264.00K 10-K · filed 2025-03-27 | |||
| 2024-06-30 | $96.00K 10-Q · filed 2024-08-12 | $207.00K derived: sum of 2 quarters · filed 2024-08-12 | ||
| 2024-03-31 | $111.00K 10-Q · filed 2024-08-12 | |||
| 2023-12-31 | $1.27M 10-K · filed 2025-03-27 | $1.00K 10-K · filed 2024-03-29 | ||
| 2023-06-30 | $437.00K 10-Q · filed 2024-08-12 | $920.00K derived: sum of 2 quarters · filed 2024-08-12 | ||
| 2023-03-31 | $483.00K 10-Q · filed 2024-08-12 | |||
| 2012-12-31 | $1.83M 10-K · filed 2014-03-05 | |||
| 2011-12-31 | $183.35K 10-K · filed 2014-03-05 | |||
| 2010-12-31 | $177.60K 10-K · filed 2012-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |